PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 5, 2024Bioanalysis8 citations

The European Bioanalysis Forum recommendation on establishing appropriate drug tolerance levels in antidrug antibody assays

View Full Paper
KCKyra J. CowanPharmacoGenetics (China)LCLysie ChampionBioanalytica (Switzerland)DDD. C. DyerUnited States Department of Agriculture

Key Points

Key points are not available for this paper at this time.

Abstract

The European Bioanalysis Forum, in collaboration with several key industry stakeholders, has recently led discussions that address international immunogenicity guidance documents, specifically the three tier approach for immunogenicity testing strategies, after more than 20 years of experience with biotherapeutics. As part of this, the strategy and methods used to assess drug tolerance across all immunogenicity assays are challenged, emphasizing that bioanalytical scientists need to consider the context-of-use of each assay. Here, recommendations for drug tolerance assessments, driven by strong scientific rationale and subject to reevaluation as needed, are provided. This includes carefully considering the drug and positive control concentrations considered to be appropriate and which tiers are most relevant for performing drug tolerance assessments.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Cowan et al. (2024) studied this question.

synapsesocial.com/papers/68e5d682b6db64358756bfechttps://doi.org/10.1080/17576180.2024.2376950
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1From 3-Tier to adaptive immunogenicity testing strategies: recommendations from the European Bioanalysis Forum2026
  2. 2Re-thinking the current paradigm for clinical immunogenicity assessment: an update from the discussion in the European Bioanalysis Forum2024 · 23 citations
  3. 3ADA assays for high-dose biologics: redefining drug tolerance through clinical insights2026 · 1 citations
  4. 4Navigating IVDR challenges for pharmacokinetic, anti-drug antibodies, and biomarker assays in early clinical research: a recommendation from the European Bioanalysis Forum2025
  5. 5From tiers to truth – a biomarker-based framework for clinically relevant immunogenicity assessment2026 · 2 citations